Trial Profile

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofirnoflast (Primary) ; Darbepoetin alfa; Epoetin alfa
Indications Myelodysplastic syndromes
Focus Proof of concept; Therapeutic Use
Sponsors Halia Therapeutics

Most Recent Events

19 Dec 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Mar 2026.
08 Dec 2025 According to a Halia Therapeutics media release, the company presented new clinical data from this study at the 67th American Society of Hematology (ASH) Annual Meeting.
08 Dec 2025 Results presented in the Halia Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com